Anti-tumour necrosis factor α therapy in rheumatoid arthritis: An update on safety

Abstract

Anti-TNFα therapy may have associated risks of serious infection, congestive heart failure, malignancy, and multiple sclerosis. The magnitude of these risks is difficult to assess. This article reviews publications on the current knowledge about the safety of these agents.